HCM
LSTA icon

Hollencrest Capital Management’s Lisata Therapeutics LSTA Stock Holding History

Hollencrest Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,194
Closed -$570K – 356
2016
Q3 		$570K Buy
+8,194
New +$660K 0.08% 167

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Hollencrest Capital Management's LSTA Position: Q4 2016 in Review

Hollencrest Capital Management sold out of Lisata Therapeutics (LSTA) in Q4 2016, closing a stake of 8,194 shares — an estimated $570K sold.

Hollencrest Capital Management first reported a position in LSTA in Q3 2016 and held it in 1 quarter. The position peaked at $570K in Q3 2016. 30 funds tracked by Wall St. Rank hold LSTA as of Q4 2016.

  • Hollencrest Capital Management reported no remaining Lisata Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Hollencrest Capital Management sold 8,194 Lisata Therapeutics shares in Q4 2016, an estimated $570K.
  • Hollencrest Capital Management first reported a position in Lisata Therapeutics in Q3 2016 and held it in 1 quarter.
  • Hollencrest Capital Management's Lisata Therapeutics position peaked at $570K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2016.

Based on Hollencrest Capital Management's 13F filing for Q4 2016, filed 30 Jan 2017.